Related references
Note: Only part of the references are listed.A cohort study of hypersensitivity reaction in patients with epithelial ovarian cancer treated with carboplatin
Tingting Sun et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2019)
Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers
Cecile Le Page et al.
BMC CANCER (2018)
Impact of carboplatin hypersensitivity and desensitization on patients with recurrent ovarian cancer
Gary Altwerger et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2018)
Platinum desensitization in patients with carboplatin hypersensitivity: A single-institution retrospective study
Gary Altwerger et al.
GYNECOLOGIC ONCOLOGY (2017)
Risk Factors of Hypersensitivity to Carboplatin in Patients with Gynecologic Malignancies
Yu-Hsiao Tai et al.
FRONTIERS IN PHARMACOLOGY (2017)
Drug Hypersensitivity and Anaphylaxis in Cancer and Chronic Inflammatory Diseases: The Role of Desensitizations
Mariana Castells
FRONTIERS IN IMMUNOLOGY (2017)
Limitations to the use of carboplatin-based therapy in advanced ovarian cancer
Christina Fotopoulou
EJC SUPPLEMENTS (2015)
Chemotherapy Hypersensitivity Reactions in Ovarian Cancer
Matthieu Picard et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2014)
Management of Hypersensitivity Reactions to Carboplatin and Paclitaxel in an Outpatient Oncology Infusion Center: A 5-Year Review
Aleena Banerji et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2014)
Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions
D. H. Moon et al.
BRITISH JOURNAL OF CANCER (2013)
Increasing the chances for platinum-sensitive ovarian cancer patients
Antonio Gonzalez
FUTURE ONCOLOGY (2013)
Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: Analysis from the GCIG CALYPSO relapsing ovarian cancer trial
Florence Joly et al.
GYNECOLOGIC ONCOLOGY (2011)
First-line treatment of advanced ovarian cancer: current research and perspectives
Claudia Marchetti et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2010)
Incidence of Carboplatin-Related Hypersensitivity Reactions in Japanese Patients With Gynecologic Malignancies
H. Koshiba et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2009)
Risk stratification for desensitization of patients with carboplatin hypersensitivity: Clinical presentation and management
Paul E. Hesterberg et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2009)
Hypersensitivity following Retreatment with Carboplatin a Decade after Completion of Primary Platinum-Based Chemotherapy
Laura Williams et al.
CASE REPORTS IN ONCOLOGY (2009)
First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence
J Sandercock et al.
BRITISH JOURNAL OF CANCER (2002)
Hypersensitivity reactions to carboplatin administration are common but not always severe: A 10-year experience
A Polyzos et al.
ONCOLOGY (2001)
Share Paper
